FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.
What happened
FDA inspected the New York State Psychiatric Institute Institutional Review Board from January 23 to February 2, 2023, as part of its bioresearch monitoring program. FDA found the IRB did not follow its written procedures for promptly reporting unanticipated problems, serious or continuing noncompliance, and suspension of IRB approval to FDA. FDA also found that on June 17, 2019, the IRB reviewed and approved FDA-regulated research at a convened meeting without at least one member whose primary concerns were in nonscientific areas.
What FDA found
The IRB did not prepare, maintain, or follow written procedures for promptly reporting unanticipated problems, serious or continuing noncompliance, and suspension or termination of IRB approval to FDA and institutional officials.
21 CFR 56.108(b); 21 CFR 56.115(a)(6); 21 CFR 56.113The IRB did not report to FDA an unanticipated problem involving risk to subjects after it determined that a subject's death by suicide was such a problem on August 9, 2021.
21 CFR 56.108(b)The IRB did not promptly report to FDA serious or continuing noncompliance by investigators for three clinical studies, despite determining or discussing such noncompliance at meetings in 2021 and 2022.
21 CFR 56.108(b)The IRB did not report to FDA its July 11, 2022, suspension of IRB approval for research under a protocol.
21 CFR 56.113; 21 CFR 56.108(b)The IRB reviewed and approved FDA-regulated research at a June 17, 2019, convened meeting without at least one member whose primary concerns were in nonscientific areas present.
21 CFR 56.108(c)
What FDA wants
Within 15 business days, FDA asks the IRB to respond in writing with corrective actions, training records or a training timeline, and revised or draft written procedures and policies with an implementation timeline. FDA also asks for corrective or preventive actions to ensure a nonscientific member is present when FDA-regulated research is reviewed.
Who should pay attention
- IRBs reviewing FDA-regulated drug studies
- research institutions and sponsors relying on this IRB
- clinical trial sponsors and contract research organizations using NYSPI IRB
This is a summary. Read the original letter on fda.gov.